Literature DB >> 19465821

Sudden death and sickle cell trait: medicolegal considerations and implications.

Lisa Scheinin1, Charles V Wetli.   

Abstract

Sickle cell trait, which affects approximately 8% of American blacks, is generally felt to be a benign condition. Exercise-related collapse in persons with sickle cell trait is a rare but serious complication. It occurs most often in military recruits and deconditioned athletes undergoing intense physical training, but can also occur in other situations in which an individual exerts himself beyond his limits of endurance. Local hypoxia causes intravascular sickling, in turn causing vascular occlusion and organ and tissue damage. This can result in rhabdomyolysis, myocardial ischemia, arrhythmias and sudden death. Risk factors include poor physical conditioning, inadequate hydration, excess heat and/or altitude, heat-retaining clothing and febrile illness. Seven cases are presented, and the implications of the diagnosis of sickle trait-associated collapse and sudden death are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19465821     DOI: 10.1097/PAF.0b013e318187dfcd

Source DB:  PubMed          Journal:  Am J Forensic Med Pathol        ISSN: 0195-7910            Impact factor:   0.921


  3 in total

1.  Sickle Cell Trait, Rhabdomyolysis, and Mortality among U.S. Army Soldiers.

Authors:  D Alan Nelson; Patricia A Deuster; Robert Carter; Owen T Hill; Vickee L Wolcott; Lianne M Kurina
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

2.  Exertional sickling: questions and controversy.

Authors:  Morey A Blinder; Sarah Russel
Journal:  Hematol Rep       Date:  2014-12-03

3.  Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening.

Authors:  Sara D Khangura; Beth K Potter; Christine Davies; Robin Ducharme; A Brianne Bota; Steven Hawken; Kumanan Wilson; Maria D Karaceper; Robert J Klaassen; Julian Little; Ewurabena Simpson; Pranesh Chakraborty
Journal:  BMC Pediatr       Date:  2021-07-01       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.